Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).

Da Silva, Diane M; Enserro, Danielle M; Mayadev, Jyoti S; Skeate, Joseph G; Matsuo, Koji; Pham, Huyen Q; Lankes, Heather A; Moxley, Katherine M; Ghamande, Sharad A; Lin, Yvonne G; Schilder, Russell J; Birrer, Michael J; Kast, W Martin

Da Silva, Diane M; Enserro, Danielle M; Mayadev, Jyoti S; Skeate, Joseph G; Matsuo, Koji; Pham, Huyen Q; Lankes, Heather A; Moxley, Katherine M; Ghamande, Sharad A; Lin, Yvonne G; Schilder, Russell J; Birrer, Michael J; Kast, W Martin.

Afiliación

Da Silva DM; Department of Obstetrics & Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California. Diane.DaSilva@med.usc.edu.
Enserro DM; Clinical Trial Development Division, NRG Oncology, Philadelphia, Pennsylvania.
Mayadev JS; Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Skeate JG; Department of Radiation Medicine and Applied Sciences, UC San Diego Medical Center, La Jolla, California.
Matsuo K; Department of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Pham HQ; Department of Obstetrics & Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Lankes HA; Department of Obstetrics & Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Moxley KM; Operations Center-Philadelphia East, NRG Oncology, Philadelphia, Pennsylvania.
Ghamande SA; Department of Obstetrics & Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Lin YG; Department of Obstetrics & Gynecology, Oklahoma University Health Science Center, Oklahoma City, Oklahoma.
Schilder RJ; Department of Gynecology/Oncology, Augusta University Medical Center, Augusta, Georgia.
Birrer MJ; Department of Obstetrics & Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Kast WM; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.

Clin Cancer Res ; 26(21): 5621-5630, 2020 11 01.

Article en En | MEDLINE | ID: mdl-32816895

Asunto(s)

Antígeno CTLA-4/genética; Ipilimumab/administración & dosificación; Recurrencia Local de Neoplasia/tratamiento farmacológico; Neoplasias del Cuello Uterino/tratamiento farmacológico; Adulto; Biomarcadores de Tumor/genética; Antígeno CTLA-4/antagonistas & inhibidores; Quimioradioterapia/efectos adversos; Quimioradioterapia/métodos; Relación Dosis-Respuesta a Droga; Femenino; Papillomavirus Humano 16/genética; Papillomavirus Humano 16/patogenicidad; Papillomavirus Humano 18/genética; Papillomavirus Humano 18/patogenicidad; Humanos; Inhibidores de Puntos de Control Inmunológico/administración & dosificación; Inhibidores de Puntos de Control Inmunológico/efectos adversos; Interferón gamma/genética; Ipilimumab/efectos adversos; Persona de Mediana Edad; Recurrencia Local de Neoplasia/genética; Recurrencia Local de Neoplasia/patología; Recurrencia Local de Neoplasia/radioterapia; Supervivencia sin Progresión; Linfocitos T/efectos de los fármacos; Linfocitos T/inmunología; Factor de Necrosis Tumoral alfa/genética; Neoplasias del Cuello Uterino/genética; Neoplasias del Cuello Uterino/patología; Neoplasias del Cuello Uterino/radioterapia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Cuello Uterino / Antígeno CTLA-4 / Ipilimumab / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google